Morepen Laboratories Limited · NSE:MOREPENLAB
Morepen Laboratories — Q2 FY2020 Earnings Presentation
15 slides from Morepen Laboratories's earnings presentation, Nov 13, 2019
Slide 1: Exchange filing cover letter for Investors Presentation Q2'FY20
IAO~EPEN Date: 13/11/2019 To, National Stock Exchange of India Ltd. BSE Limited Exchange Plaza, Bandra Kurla Complex, Floor 25, Phiroze Jeejeebhoy Towers, Bandra (East), Mumbai- 400 051 Dalal Street, Mumbai- 400 001 Tel No: (022) 26598100- 8114 Phones: 91-22-22721233/4 Fax No: (022) 26598120 Fax: 91
Slide 2: Investors Presentation (Q2'FY20) November 2019
“ I CHOOSE INVESTORS PRESENTATION (Q2’FY20) NOVEMBER 2019
Slide 3: Disclaimer
Disclaimer: This presentation has been prepared by Morepen Laboratories Limited (“Company”) solely for information purposes without regard to any specific objectives, financial situations or informational needs of any particular person. This presentation contains expressed or implied forward looking
Slide 4: Highlights of H1'FY20 Performance
Highlights of H1’FY20 Performance ₹ crores • Net Sales Revenue in H1’FY20 up by 24.2% at Rs. 383.30 crore as compared to H1’FY19 . • Net Profit before tax up by 87.5% at Rs. 18.10 crore against Rs.9.65 crores in H1’FY19 . • Cash Profits up by 32.4% at Rs. 36.63 crore against Rs.27.67 crores in H1’FY
Slide 5: Highlights of Q2'FY20 Performance
Highlights of Q2’FY20 Performance ₹ crores • Net Sales Revenue in Q2’FY20 up by 23.1% at Rs. 196.60 crore as compared to Q2’FY19 . • Net Profit before tax up by 36% at Rs. 9.69 crore against Rs.7.10 crores in Q2’FY19 . • Cash Profits up by 6.4% at Rs. 17.32 crore against Rs.16.28 crores last year sa
Slide 6: Segments wise growth
Segments wise growth: ₹ crores • Overall business for the Quarter (Q2’FY20) has grown at 24% as compared to Q2’FY19 216 • API Business has shown extremely good results having grown at 30% for the Q2’FY20 and still contributes 55% to the consolidated sales revenue and 59% to 24% the standalone revenu
Slide 7: API: Export leads the way
API: Export leads the way ₹ crores • API business retains its lion’s share of 55% and has grown at 30% API Revenues on quarter on quarter basis. 116.37 • API Export business has got a jump of 43% with • Montelukast -112% 30% • Loratadine - 30% • Atorvastatin - 33% 89.47 • New Molecules - 63% growth
Slide 8: APAC Region outperforms
APAC Region outperforms ₹ crores • Asia pacific Export business has got 52% share in the export API Export business for the quarter and a jump of 44% as compared to Q2’FY19, with major growth registered from following markets: 92.48 • Bangladesh • China • Sri Lanka 43% • Israel 64.77 • Egypt • Korea
Slide 9: Devices Business – Strong Quarter
Devices Business – Strong Quarter ₹ crores • Home Devices portfolio has been growing with fast pace and has recorded a growth of 30% during the quarter. 45.52 • Blood Gluco Monitors sales have marked a growth of 37% in Q2’FY20 as against 30% Q2’FY19. Total Gluco monitors installed have crossed 3.20
Slide 10: Prescription drugs sales up
Prescription drugs sales up Branded Formulations ₹ crores • Branded Prescription (Rx) products has grown by 6% during the Q2’FY’20 with major contribution coming from main brands like Rhythmix, Acifix, Klarim, Eradiclave, Bacikid, Metmore , Intebac and Cefopen. 10.37 6% • Overall Finished Dosages ha
Slide 11: OTC Business gains momentum
OTC Business gains momentum ₹ crores • Total OTC category has registered a growth of 15% during the quarter and has 15.04 shown better recovery. 15% • Isabgol and Lemolate brands have grown by 41% and 12% respectively . • OTC Business has launched many new products to its Health Basket in the nutrit
Slide 12: Net Profit before tax rises
Net Profit before tax rises ₹ crores Net Standalone Revenue • EBIDTA number has grown up by 32% during the H1’FY20 and as compared to corresponding H2’FY19 202.70 • Cash Profits during H1’FY20 and Cash surplus has increased by 32.4% as 25% compared to H1’FY19. • Net profit before tax has risen to Rs
Slide 13: Q2'FY20 Performance - Standalone
Q2’FY20 Performance - Standalone ₹ crores Y-o-Y Y-o-Y Q2’FY20 Q2’FY19 Growth H1’FY20 H1’FY19 Growth Net Revenue 202.70 162.14 25.0% 392.44 313.06 25.4% Expenditure 184.99 145.56 27.1% 355.01 284.65 24.7% EBIDTA 17.71 16.59 6.8% 37.44 28.40 31.8% Interest 0.39 0.31 26% 0.81 0.74 9.5% Cash Surplus 17.
Slide 14: Q2'FY20 Performance - Consolidated
Q2’FY20 Performance - Consolidated ₹ crores Y-o-Y Y-o-Y Q2’FY20 Q2’FY19 Growth H1’FY20 H1’FY19 Growth Net Revenue 216.24 174.07 24.2% 419.50 337.88 24.2% Expenditure 198.37 157.18 26.2% 382.02 308.73 23.7% EBIDTA 17.87 16.90 5.8% 37.48 29.15 28.6% Interest 0.39 0.32 23.9% 0.82 0.76 8% Cash Surplus 1
Slide 15: Thank You
Tran You Fg MOREPEN The Joy Of Growing Together
Morepen Laboratories — Q2 FY2020 Earnings Presentation on 6ix